Expiring patents can be a catalyst for M&A in the life sciences industry as pharmaceutical and biotechnology companies seek to maintain revenue streams and competitive advantages. In this edition of Beyond the Deal, our...more
4/14/2025
/ Acquisitions ,
Artificial Intelligence ,
Biosimilars ,
Biotechnology ,
Competition ,
Generic Drugs ,
Life Sciences ,
Mergers ,
Patent Expiration ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs
The U.S. Supreme Court on May 18, 2023 delivered its decision on the scope of the patent enablement requirement, set forth in 35 U.S.C. § 112, in the antibody dispute Amgen, Inc. v. Sanofi. While the parties obtained...more
Doctrine of equivalents (DOE) can be applied as a mechanism to hold a party liable for patent infringement even if the product or process does not literally infringe a patent claim, if the difference is “insubstantial”....more
11/4/2021
/ Biotechnology ,
CAFC ,
Doctrine of Equivalents ,
Intellectual Property Protection ,
International Trade Commission (ITC) ,
Life Sciences ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs